CDK4 and CDK6 Inhibition in Breast Cancer — A New Standard
Breast cancer is the most prevalent type of malignant neoplasm worldwide, and estrogen-receptor (ER)–positive breast cancer is the most common phenotype. Outcomes continue to improve, but many patients present with advanced disease or have recurrence of disease that progressively becomes resistant t...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2016-11, Vol.375 (20), p.1993-1994 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1994 |
|---|---|
| container_issue | 20 |
| container_start_page | 1993 |
| container_title | The New England journal of medicine |
| container_volume | 375 |
| creator | Wolff, Antonio C |
| description | Breast cancer is the most prevalent type of malignant neoplasm worldwide, and estrogen-receptor (ER)–positive breast cancer is the most common phenotype. Outcomes continue to improve, but many patients present with advanced disease or have recurrence of disease that progressively becomes resistant to endocrine therapy. Efforts to enhance responsiveness to treatment and to overcome primary or acquired resistance through cotargeting of estrogen and cell proliferation–survival signaling pathways led to the recent approval of phosphatidylinositol 3-kinase–Akt–mammalian target of rapamycin (PI3K/Akt/mTOR) and cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors for the treatment of advanced ER-positive, human epidermal growth factor receptor 2 . . . |
| doi_str_mv | 10.1056/NEJMe1611926 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1851691793</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1851691793</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-92babe632147cc42d22e9d8c2d1d6771fca8ccaac26c5ebf983a1ef872913f0f3</originalsourceid><addsrcrecordid>eNpt0EFPwyAYBmBiNG5Ob54NiR48WOUDSkviZdap0zkP6rmhlMYuazuhjfHmj_AX-kvEbBpjhAMcHt58vAjtAjkGEoqT6ej61oAAkFSsoT6EjAWcE7GO-oTQOOCRZD205dyM-AVcbqIejWToN-2j0-T8hmNV59hfBB7XT2VWtmVT47LGZ9Yo1-JE1dpY_PH2jod4al7wfesfKJtvo41CzZ3ZWZ0D9Hgxekiugsnd5TgZTgLNgbeBpJnKjGAUeKQ1pzmlRuaxpjnkIoqg0CrWWilNhQ5NVsiYKTBFHFEJrCAFG6DDZe7CNs-dcW1alU6b-VzVpulcCnEIQoL_qKf7f-is6Wztp_OKA6UiZsKro6XStnHOmiJd2LJS9jUFkn61mv5u1fO9VWiXVSb_wd81enCwBFXl0trMqv9zPgGdBno9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1841226836</pqid></control><display><type>article</type><title>CDK4 and CDK6 Inhibition in Breast Cancer — A New Standard</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Wolff, Antonio C</creator><creatorcontrib>Wolff, Antonio C</creatorcontrib><description>Breast cancer is the most prevalent type of malignant neoplasm worldwide, and estrogen-receptor (ER)–positive breast cancer is the most common phenotype. Outcomes continue to improve, but many patients present with advanced disease or have recurrence of disease that progressively becomes resistant to endocrine therapy. Efforts to enhance responsiveness to treatment and to overcome primary or acquired resistance through cotargeting of estrogen and cell proliferation–survival signaling pathways led to the recent approval of phosphatidylinositol 3-kinase–Akt–mammalian target of rapamycin (PI3K/Akt/mTOR) and cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors for the treatment of advanced ER-positive, human epidermal growth factor receptor 2 . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMe1611926</identifier><identifier>PMID: 27959592</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>1-Phosphatidylinositol 3-kinase ; AKT protein ; Breast cancer ; Breast Neoplasms ; Cancer therapies ; Cell proliferation ; Cell survival ; Cyclin-dependent kinase 4 ; Cyclin-Dependent Kinase 6 ; Cyclin-dependent kinases ; Endocrine therapy ; Epidermal growth factor ; Estrogen receptors ; Humans ; Inhibitor drugs ; Neoplasia ; Phenotypes ; Proto-Oncogene Proteins ; Rapamycin ; TOR protein</subject><ispartof>The New England journal of medicine, 2016-11, Vol.375 (20), p.1993-1994</ispartof><rights>Copyright © 2016 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-92babe632147cc42d22e9d8c2d1d6771fca8ccaac26c5ebf983a1ef872913f0f3</citedby><cites>FETCH-LOGICAL-c414t-92babe632147cc42d22e9d8c2d1d6771fca8ccaac26c5ebf983a1ef872913f0f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMe1611926$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1841226836?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,782,786,2761,2762,26110,27931,27932,52389,54071,64392,64394,64396,72476</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27959592$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wolff, Antonio C</creatorcontrib><title>CDK4 and CDK6 Inhibition in Breast Cancer — A New Standard</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Breast cancer is the most prevalent type of malignant neoplasm worldwide, and estrogen-receptor (ER)–positive breast cancer is the most common phenotype. Outcomes continue to improve, but many patients present with advanced disease or have recurrence of disease that progressively becomes resistant to endocrine therapy. Efforts to enhance responsiveness to treatment and to overcome primary or acquired resistance through cotargeting of estrogen and cell proliferation–survival signaling pathways led to the recent approval of phosphatidylinositol 3-kinase–Akt–mammalian target of rapamycin (PI3K/Akt/mTOR) and cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors for the treatment of advanced ER-positive, human epidermal growth factor receptor 2 . . .</description><subject>1-Phosphatidylinositol 3-kinase</subject><subject>AKT protein</subject><subject>Breast cancer</subject><subject>Breast Neoplasms</subject><subject>Cancer therapies</subject><subject>Cell proliferation</subject><subject>Cell survival</subject><subject>Cyclin-dependent kinase 4</subject><subject>Cyclin-Dependent Kinase 6</subject><subject>Cyclin-dependent kinases</subject><subject>Endocrine therapy</subject><subject>Epidermal growth factor</subject><subject>Estrogen receptors</subject><subject>Humans</subject><subject>Inhibitor drugs</subject><subject>Neoplasia</subject><subject>Phenotypes</subject><subject>Proto-Oncogene Proteins</subject><subject>Rapamycin</subject><subject>TOR protein</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0EFPwyAYBmBiNG5Ob54NiR48WOUDSkviZdap0zkP6rmhlMYuazuhjfHmj_AX-kvEbBpjhAMcHt58vAjtAjkGEoqT6ej61oAAkFSsoT6EjAWcE7GO-oTQOOCRZD205dyM-AVcbqIejWToN-2j0-T8hmNV59hfBB7XT2VWtmVT47LGZ9Yo1-JE1dpY_PH2jod4al7wfesfKJtvo41CzZ3ZWZ0D9Hgxekiugsnd5TgZTgLNgbeBpJnKjGAUeKQ1pzmlRuaxpjnkIoqg0CrWWilNhQ5NVsiYKTBFHFEJrCAFG6DDZe7CNs-dcW1alU6b-VzVpulcCnEIQoL_qKf7f-is6Wztp_OKA6UiZsKro6XStnHOmiJd2LJS9jUFkn61mv5u1fO9VWiXVSb_wd81enCwBFXl0trMqv9zPgGdBno9</recordid><startdate>20161117</startdate><enddate>20161117</enddate><creator>Wolff, Antonio C</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20161117</creationdate><title>CDK4 and CDK6 Inhibition in Breast Cancer — A New Standard</title><author>Wolff, Antonio C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-92babe632147cc42d22e9d8c2d1d6771fca8ccaac26c5ebf983a1ef872913f0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>1-Phosphatidylinositol 3-kinase</topic><topic>AKT protein</topic><topic>Breast cancer</topic><topic>Breast Neoplasms</topic><topic>Cancer therapies</topic><topic>Cell proliferation</topic><topic>Cell survival</topic><topic>Cyclin-dependent kinase 4</topic><topic>Cyclin-Dependent Kinase 6</topic><topic>Cyclin-dependent kinases</topic><topic>Endocrine therapy</topic><topic>Epidermal growth factor</topic><topic>Estrogen receptors</topic><topic>Humans</topic><topic>Inhibitor drugs</topic><topic>Neoplasia</topic><topic>Phenotypes</topic><topic>Proto-Oncogene Proteins</topic><topic>Rapamycin</topic><topic>TOR protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wolff, Antonio C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wolff, Antonio C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CDK4 and CDK6 Inhibition in Breast Cancer — A New Standard</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2016-11-17</date><risdate>2016</risdate><volume>375</volume><issue>20</issue><spage>1993</spage><epage>1994</epage><pages>1993-1994</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>Breast cancer is the most prevalent type of malignant neoplasm worldwide, and estrogen-receptor (ER)–positive breast cancer is the most common phenotype. Outcomes continue to improve, but many patients present with advanced disease or have recurrence of disease that progressively becomes resistant to endocrine therapy. Efforts to enhance responsiveness to treatment and to overcome primary or acquired resistance through cotargeting of estrogen and cell proliferation–survival signaling pathways led to the recent approval of phosphatidylinositol 3-kinase–Akt–mammalian target of rapamycin (PI3K/Akt/mTOR) and cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors for the treatment of advanced ER-positive, human epidermal growth factor receptor 2 . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>27959592</pmid><doi>10.1056/NEJMe1611926</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2016-11, Vol.375 (20), p.1993-1994 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1851691793 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | 1-Phosphatidylinositol 3-kinase AKT protein Breast cancer Breast Neoplasms Cancer therapies Cell proliferation Cell survival Cyclin-dependent kinase 4 Cyclin-Dependent Kinase 6 Cyclin-dependent kinases Endocrine therapy Epidermal growth factor Estrogen receptors Humans Inhibitor drugs Neoplasia Phenotypes Proto-Oncogene Proteins Rapamycin TOR protein |
| title | CDK4 and CDK6 Inhibition in Breast Cancer — A New Standard |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T05%3A19%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CDK4%20and%20CDK6%20Inhibition%20in%20Breast%20Cancer%20%E2%80%94%20A%20New%20Standard&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Wolff,%20Antonio%20C&rft.date=2016-11-17&rft.volume=375&rft.issue=20&rft.spage=1993&rft.epage=1994&rft.pages=1993-1994&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMe1611926&rft_dat=%3Cproquest_cross%3E1851691793%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1841226836&rft_id=info:pmid/27959592&rfr_iscdi=true |